Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide reversibly blocks acetylcholinesterase, the enzyme that degrades acetylcholine. By preserving acetylcholine at nerve‑muscle and autonomic synapses, it amplifies cholinergic signaling, which improves neuromuscular transmission and stabilises blood pressure upon standing.

The specific dose of Mestinon is individualized by the prescribing clinician based on the patient’s condition, severity, renal function and response to therapy. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Mestinon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon (pyridostigmine) is a reversible, peripherally acting cholinesterase inhibitor, similar to neostigmine but with a longer duration of action and fewer central nervous system effects. It is preferred for chronic outpatient management of myasthenia gravis, whereas other agents may be used in acute settings.

Mestinon should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in humid or excessively hot environments.

Mestinon is taken orally, usually as a tablet, with or without food as directed by the prescriber. The dose may be divided throughout the day to maintain steady plasma levels and to minimise gastrointestinal side effects.

The most serious risks include cholinergic crisis, which can cause severe muscle weakness and respiratory failure, as well as profound bradycardia, bronchospasm and rare allergic reactions such as anaphylaxis. Immediate medical attention is required if these symptoms occur.

Mestinon is contraindicated in individuals with known hypersensitivity to pyridostigmine or other cholinesterase inhibitors, and it should be used with caution in patients with severe renal impairment, asthma, or cardiac conduction abnormalities unless specifically advised by a physician.